The Food and Drug Administration (FDA) is looking for patient perspectives on the impact of narcolepsy on daily life as well as the available therapies for narcolepsy. The FDA is requesting this information as part of its Patient-Focused Drug Development initiative. Narcolepsy was one of 20 diseases chosen for the initiative. Participants have the option to attend in person or by webcast.
It is vitally important that the narcolepsy community be well represented at this meeting. By offering comments and sharing their perspectives, PWNs can help influence the FDA’s future regulatory decisions about approved and new narcolepsy treatments. Don’t miss this opportunity to shape the future of narcolepsy treatment!
There are two ways to participate:
1. Attend the public meeting
On September 24, the FDA is holding a public meeting on Narcolepsy Patient-Focused Drug Development. There will be two topics of discussion: the impact of narcolepsy on daily life (topic 1) and currently available therapies to treat the condition (topic 2). The questions for discussion on these topics can be found on the FDA’s meeting registration page.
For each topic, a preselected panel of patients and patient representatives/advocates will present comments to begin the dialogue and followed by a facilitated discussion inviting comments from those in attendance.
There will also be an opportunity for patients, patient representatives and others to provide comments on issues other than topics 1 and 2 during an Open Public Comment session. Sign up for Open Public Comment will take place at the meeting.
Space at the meeting is limited, and registration will close on September 13.
Additional Meeting Information
|Date:||September 24, 2013|
|Time:||1 p.m. to 5 p.m.|
|Location:||FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A
Silver Spring, MD 20993(Information about arrival to FDA’s White Oak campus)
To register for this meeting, visit: http://patientfocusednarcolepsy.eventbrite.com
Registration will close on September 13, 2013.
2. Attend the public meeting via webcast
For those who are not able to travel to Washington, DC, attendance via webcast is available. See the FDA’s meeting registration page to register for the webcast.
Webcast capacity is limited, and registration will close on September 13.